Patents Issued in June 21, 2016
-
Patent number: 9371254Abstract: The manufacturing method of the honeycomb structure has a forming step of forming a forming raw material into a plurality of quadrangular prismatic honeycomb formed bodies each having partition walls, a firing step of firing the plurality of honeycomb formed bodies to form a plurality of quadrangular prismatic honeycomb fired bodies, a sheet-like bonding material attaching step of attaching sheet-like bonding materials to at least part of side surfaces of at least part of the plurality of honeycomb fired bodies, a honeycomb block body preparing step of preparing a honeycomb block body in which the plurality of honeycomb fired bodies are stacked, by assembling the plurality of quadrangular prismatic honeycomb fired bodies while bonding the side surfaces thereof to one another by the bonding materials, and a grinding step of grinding a circumferential portion of the honeycomb block body to obtain the honeycomb structure.Type: GrantFiled: February 10, 2015Date of Patent: June 21, 2016Assignee: NGK Insulators, Ltd.Inventors: Yutaka Ishii, Kazunari Akita, Yoshihiro Sato, Masayuki Nate
-
Patent number: 9371255Abstract: The present invention relates to mixed oxide compositions, to the use thereof as a catalyst for cleavage of alkyl tert-alkyl ethers or tertiary alcohols, and to a process for cleaving alkyl tert-alkyl ethers or tertiary alcohols to isoolefins and alcohol or water.Type: GrantFiled: March 7, 2012Date of Patent: June 21, 2016Assignee: Evonik Degussa GmbHInventors: Markus Winterberg, Christian Böing, Dietrich Maschmeyer, Asli Nau, Horst-Werner Zanthoff, Thomas Quandt, Christian Schulze Isfort
-
Patent number: 9371256Abstract: A heated petroleum-derived hydrocarbon is contacted with a triglyceride feed in a thermal cracking zone to decompose and remove impurities prior to hydrotreating the mixture to fuel range hydrocarbon. This process allows the use of a variety of low cost triglyceride feeds while reducing fouling of process equipment and catalyst. The process also reduces the use of chemicals required for conventional degumming of triglyceride feeds.Type: GrantFiled: March 31, 2014Date of Patent: June 21, 2016Assignee: PHILLIPS 66 COMPANYInventors: Jianhua Yao, Edward L. Sughrue, II, Dhananjay B. Ghonasgi, Xiaochun Xu
-
Patent number: 9371257Abstract: A method for the oxidative coupling of hydrocarbons includes providing an oxidative catalyst inside a reactor and carrying out the oxidative coupling reaction under a set of reaction conditions. The reactor surfaces that contact the reactants and products do not provide a significant detrimental catalyzing effect. In an embodiment the reactor contains an inert lining or a portion of the reactor inner surface is treated to reduce the detrimental catalytic effects. In an embodiment the reactor contains a lining that includes an oxidative catalyst.Type: GrantFiled: February 11, 2015Date of Patent: June 21, 2016Assignee: Fina Technology, Inc.Inventors: Sivadinarayana Chinta, Joseph L. Thorman
-
Patent number: 9371258Abstract: A method for producing high density fuels from isoprene which can be produced via biosynthetic routes using biomass sugars as feedstock. This allows for the production of isoprene and isoprene-derived fuels from abundant waste materials with the potential to significantly reduce DoD carbon emissions. Embodiments of the invention describe a method for conversion of isoprene to full performance jet and diesel fuels. Isoprene can be selectively oligomerized to generate a distribution of branched chain hydrocarbons. Combination of an oligomerization catalyst with a metathesis catalyst allows for the synthesis of high density cyclic fuels with performance advantages (increased density and volumetric net heat of combustion) over conventional petroleum-based fuels.Type: GrantFiled: June 25, 2014Date of Patent: June 21, 2016Assignee: The United States of America as Represented by the Secretary of the NavyInventor: Benjamin G. Harvey
-
Patent number: 9371259Abstract: Provided is a method for preparing vinyl chloride with acetylene and dichlorethane for large-scale industrial production. Acetylene, dichlorethane vapor and hydrogen chloride gas at a molar ratio of 1:(0.3-1.0):(0-0.20) are mixed; the raw mixed gas is preheated; the preheated raw mixed gas passes through a reactor containing a catalyst and reacts; the resultant mixed gas is cooled to 30-50° C. and pressurized to 0.4-1.0 MPa, and then cooled to ambient temperature, and further frozen to ?25-15° C. for liquefaction isolation, and unliquefied gas is recycled and reused; liquefied liquid is sent to a rectifying tower for rectification, and vinyl chloride monomers meeting polymerization requirements are obtained. The present invention has the advantages of eliminating mercury contamination completely, simplifying the reactor structure, recycling hydrogen chloride and acetylene, reducing waterwash process, avoiding mass production of waste acid and improving utilization of chlorine.Type: GrantFiled: July 12, 2012Date of Patent: June 21, 2016Assignees: SHANGHAI ADVANCED RESEARCH INSTITUTE, CHINESE ACADEMY OF SCIENCES, ZHONGKE YIGONG (SHANGHAI) CHEMICAL TECHNOLOGY CO., LTD.Inventors: Biao Jiang, Jinguang Zhong
-
Patent number: 9371260Abstract: Provided is a method for producing refined glycerin alkyl ether at a high recovery rate by removing glycerin from a mixture containing glycerin and glycerin alkyl ether. A method for producing refined glycerin alkyl ether comprising the following steps (1) and (2): step (1): bringing a mixture containing glycerin and glycerin alkyl ether into contact with a cation exchange resin; step (2): bringing the cation exchange resin into contact with a solvent having an SP value of from 20.5 to 34 (MPa)1/2 to obtain an eluate.Type: GrantFiled: April 24, 2013Date of Patent: June 21, 2016Assignee: KAO CORPORATIONInventor: Yukiteru Sugiyama
-
Patent number: 9371261Abstract: An aim of the present invention is to produce, from glycerol, a bioresourced acrylic acid, that is to say an acrylic acid essentially based on a carbon source of natural origin, meeting all the quality criteria of monomers customarily used as starting material in processes for polymerization of acrylic acid and of its esters, via an economical process. The process according to the invention comprises a final stage of extraction of acrylic acid by fractional crystallization applied to one of the effluents resulting from the acrylic acid purification chain, the location of this final stage possibly depending on the initial feedstock treated, the nature and the source of the glycerol used in the process, purity specifications to be achieved for the final acrylic acid, or finally economic criteria.Type: GrantFiled: June 29, 2010Date of Patent: June 21, 2016Assignee: ARKEMA FRANCEInventor: Michel Fauconet
-
Patent number: 9371262Abstract: A direct acid catalyzed intermolecular electrocyclic rearrangement process for the preparation of linear and cyclic homoallylic ester and amides. A one step intermolecular electrocyclic rearrangement process includes the step of reacting a beta, gamma-unsaturated aldehyde or ketone, in which the beta, gamma-unsaturation is not part of an aromatic ring, with another aldehyde or a secondary aldimine in the presence of an acid.Type: GrantFiled: October 26, 2012Date of Patent: June 21, 2016Assignee: Givaudan S.A.Inventors: Yue Zou, Li Jun Zhou, Changming Ding, Andreas Goeke
-
Patent number: 9371263Abstract: Disclosed herein are compounds, compositions and methods for preventing and treating diseases such as intracerebral hemorrhage, cancer, or conditions associated with damaged cells, activated lymphocytes, or microbial products. The disclosed compounds are curcumin analogs. The curcumin analogs possess anti-inflammatory and antioxidant properties, which in part, reduce AP-1 and NF-?B activity.Type: GrantFiled: September 22, 2014Date of Patent: June 21, 2016Assignees: Augusta University Research Institute, Inc., East China Normal UniversityInventors: Cargill H. Alleyne, Jr., Krishnan M. Dhandapani, Ken Wen, MingLiang Ma, WenJing Hu
-
Patent number: 9371264Abstract: Compounds represented by formulae I, II, III, and IV including pro-drugs for treprostinil and prostacyclin analogs. Uses include treatment of pulmonary hypertension (PH) or pulmonary arterial hypertension (PAH). The structures of the compounds can be adapted to the particular application for a suitable treatment dosage. Transdermal applications can be used.Type: GrantFiled: January 13, 2014Date of Patent: June 21, 2016Assignee: CORSAIR PHARMA, INC.Inventors: Cyrus K. Becker, Jürg R. Pfister, Gwenaella Rescourio, Meenakshi S. Venkatraman, Xiaoming Zhang
-
Patent number: 9371265Abstract: Embodiments are directed to JAK kinase inhibiting prodrug compounds of Formula Ib, containing a promoiety that results in alcohol derivative of the parent compound upon removal and methods of using an effective amount of said prodrug compounds in the treatment of a JAK-mediated disease or disorder in a subject. Preferred promoieties include phosphate, phosphonate, phosphate salt, sulfate, or sulfate salt.Type: GrantFiled: March 26, 2013Date of Patent: June 21, 2016Inventors: Federica Pericle, Jeremy A. Ross
-
Patent number: 9371266Abstract: Catalysts and methods for their manufacture and use for the dehydrogenation of alcohols are disclosed. The catalysts and methods utilize a highly dispersible alumina, for example, boehmite or pseudoboehmite, to form catalysts that exhibit high dehydrogenation activities. Specifically, the catalysts include Cu that is highly dispersed by reaction of an alumina formed by peptizing of boehmite or pseudoboehmite and precursors of ZrO2, ZnO and CuO.Type: GrantFiled: April 1, 2014Date of Patent: June 21, 2016Assignee: BASF CORPORATIONInventors: Rostam Jai Madon, Peter Nagel, Deepak S. Thakur
-
Patent number: 9371267Abstract: A method for preparation of secondary alcohols with a high proportion of hydroxyl group at the C2 position is disclosed. Alkyl carboxylates, high in alpha-methylcarboxylate content, are produced via reaction of an alpha-olefin and a carboxylic acid in the presence of a cerium catalyst. The resultant alkyl carboxylate is hydrolyzed to yield a secondary alcohol with a high 2-hydroxyl content. The secondary alcohol may be used to prepare esters, especially phthalate esters or cyclohexanoate diesters, which are useful as plasticizers. These esters are more effective as plasticizers than esters derived from other secondary alcohols due to their high C2 point of attachment.Type: GrantFiled: November 16, 2010Date of Patent: June 21, 2016Assignee: ExxonMobil Chemical Patents Inc.Inventors: Karla S. Colle, Allen D. Godwin
-
Patent number: 9371268Abstract: An asymmetric chain carbonate can be produced in a single-step reaction comprising a step of reacting methyl nitrite, carbon monoxide, and 0.05-1.5 moles of an aliphatic alcohol having 2-6 carbon atoms or an alicyclic alcohol having 5-6 carbon atoms per one mole of methyl nitrile in a gaseous phase in the presence of a solid catalyst comprising a platinum group metal or a compound thereof placed on a support.Type: GrantFiled: August 31, 2009Date of Patent: June 21, 2016Assignee: UBE INDUSTRIES, LTD.Inventors: Koji Abe, Akikazu Ito
-
Patent number: 9371269Abstract: The present invention provides a method for preparing dialkyl carbonate from urea or alkyl carbamate and alkyl alcohol using an ionic liquid comprising a cation, which produces a hydrogen ion, and a hydrophobic anion containing fluorine with high temperature stability in the presence of catalyst containing a metal oxide or hydrotalcite. Since the present invention can prepare dialkyl carbonate at a pressure lower than those of existing methods, it does not require an expensive pressure control device and peripheral devices for maintaining high pressure including the installation cost. It is also the method for preparing a dialkyl carbonate with high yield, thus improving economical efficiency. Moreover, the method of the present invention hardly produces any waste during the process and is thus an eco-friendly method.Type: GrantFiled: December 9, 2013Date of Patent: June 21, 2016Assignee: RESEARCH INSTITUTE OF INDUSTRIAL SCIENCE & TECHNOLOGYInventors: Jae Cheon Koh, Chul Ung Kim, Yun Min Kim
-
Patent number: 9371270Abstract: Embodiments of the present disclosure are directed to a compound represented by Formula 1, and to organic light-emitting diodes including the compound.Type: GrantFiled: November 13, 2012Date of Patent: June 21, 2016Assignee: Samsung Display Co., Ltd.Inventors: Jin-O Lim, Seok-Hwan Hwang, Young-Kook Kim, Hye-Jin Jung, Sang-Hyun Han, Soo-Yon Kim, Eun-Jae Jeong, Jun-Ha Park, Eun-Young Lee, Il-Soo Oh, Jong-Hyuk Lee
-
Patent number: 9371271Abstract: In production of a cationic lipid having at least one methylene group sandwiched between adjacent two cis form double bonds in the molecule, isomerization from a cis form to a trans form is suppressed. A compound represented by the following formula (I): R1—X??(I) (in Formula, R1 represents a hydrocarbon group having at least one methylene group sandwiched between adjacent two cis form double bonds in the molecule and having the carbon number of 8 to 24 and X represents a releasing group) is reacted with (B) a compound having at least one of each of tertiary amino group and hydroxyl group in the molecule in a saturated hydrocarbon solvent having the carbon number of 5 to 10 in the presence of an alkali catalyst.Type: GrantFiled: June 21, 2013Date of Patent: June 21, 2016Assignee: NOF CORPORATIONInventors: Kazuhiro Kubo, Kota Tange, Masaki Ohta
-
Patent number: 9371272Abstract: Objects are to provide efficient methods for producing hydrogen or heavy hydrogens and for hydrogenating (protiating, deuterating or tritiating) an organic compound, and to provide an equipment and the like used therefor. A method for producing hydrogen or heavy hydrogens, containing subjecting water or heavy water to mechanochemical reaction in the presence of a catalyst metal, in which an energy density of a rotational acceleration of 75 G or more is applied to water or heavy water for 25 minutes or more, a method for producing a hydrogenated (protiated, deuterated or tritiated) organic compound, a method for hydrogenating (protiating, deuterating or tritiating) an organic compound, a method for dehalogenating an organic compound having halogen, and a ball for mechanochemical reaction are provided.Type: GrantFiled: February 8, 2013Date of Patent: June 21, 2016Assignee: Shiono Chemical Co., Ltd.Inventors: Hironao Sajiki, Yasunari Monguchi, Yoshinari Sawama, Shinichi Kondo, Yasushi Sasai
-
Patent number: 9371273Abstract: Ether-amide compounds having the formula RaRbC(OR1)—CHRc—CONR2R3 are described. Also described, are processes for the preparation and use thereof, especially as solvents, for example in phytosanitary formulations.Type: GrantFiled: August 26, 2014Date of Patent: June 21, 2016Assignee: RHODIA OPERATIONSInventors: Massimo Guglieri, Olivier Jentzer
-
Patent number: 9371274Abstract: [Problem] Provision of a novel compound having read-through activity and a drug for the treatment of nonsense mutation-type disease containing this compound. [Solution] A compound represented by the following general formula (1): and a pharmaceutical composition containing this compound.Type: GrantFiled: May 30, 2014Date of Patent: June 21, 2016Assignee: THE UNIVERSITY OF TOKYOInventors: Yoshio Hayashi, Akihiro Taguchi, Fumika Yakushiji, Yuri Yamazaki, Ryoichi Matsuda, Masataka Shiozuka
-
Patent number: 9371275Abstract: There is provided a compound of Formula (I) and salts thereof, where R1 is an oxime or an alkylated oxime; the alkylated oxime comprises a linear or branched alkyl group of length C1 to C5; and R2 are each independently (a) an unsubstituted or substituted linear or branched alkyl group of chain length C1-7, (b) an aryl substituted alkyl group, where the aryl group is substituted, (c) an alkoxy substituted alkyl group, where the alkoxy group is substituted by a methoxy group or an alkoxy group substituted with an alkoxy group, or (d) an H atom, where the substituents in (a) and (b) are hydroxy, alkoxy, acyloxy, alkoxycarbonyloxy, amino, aryl, nitro, oxo or fluoro groups. The compounds may be used as a medicament.Type: GrantFiled: November 12, 2013Date of Patent: June 21, 2016Assignee: SWEDISH PHARMA ABInventors: Leif A. Eriksson, Lennart Löfgren
-
Patent number: 9371276Abstract: The invention relates to the compounds and compositions of Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprises a salt of metformin and the methods for treating or preventing metabolic syndrome, prediabetes and diabetes may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of diabetes mellitus, obesity, lipid disorders, hypertriglyceridemia, hyperglycemia, hyperinsulinemia and insulin resistance.Type: GrantFiled: November 11, 2015Date of Patent: June 21, 2016Inventor: Mohan Murali Alapati
-
Patent number: 9371277Abstract: Benzamide compounds and derivatives thereof, as can be used for selective inhibition of the SIRT2 enzyme and/or therapeutic use in the treatment of Huntington's disease.Type: GrantFiled: December 23, 2013Date of Patent: June 21, 2016Assignees: Northwestern University, The General Hospital CorporationInventors: Richard B. Silverman, Hua Wang, Mohammad Khanfar, Aleksey G. Kazantsev
-
Patent number: 9371278Abstract: The present invention relates to novel sulfur derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of chemokine receptors.Type: GrantFiled: April 10, 2014Date of Patent: June 21, 2016Assignee: Allergan, Inc.Inventors: Haiqing Yuan, Richard L. Beard, Xiaoxia Liu, John E. Donello, Veena Viswanath, Michael E. Garst
-
Patent number: 9371279Abstract: The present invention relates to a transesterification process of specific compounds comprising isoprenoid units.Type: GrantFiled: August 7, 2013Date of Patent: June 21, 2016Assignee: DSM IP ASSETS B.V.Inventors: Werner Bonrath, Alex Gaa, Claude Stritt
-
Patent number: 9371280Abstract: There are provided compounds of the formula wherein X, Y, Z, R1, R2 and R3 are as described herein and enantiomers and pharmaceutically acceptable salts and esters thereof. The compounds are useful as anticancer agents.Type: GrantFiled: May 29, 2013Date of Patent: June 21, 2016Assignee: HOFFMANN-LA ROCHE INC.Inventors: David Joseph Bartkovitz, Xin-Jie Chu, George Kenneth Ehrlich, Jin-Jun Liu, Hanspeter Michel, Binh Thanh Vu, Chunlin Zhao
-
Patent number: 9371281Abstract: Described herein are compounds and pharmaceutical compositions containing such compounds, which inhibit the activity of histone deacetylase 8 (HDAC8). Also described herein are methods of using such HDAC8 inhibitors, alone and in combination with other compounds, for treating diseases or conditions that would benefit from inhibition of HDAC8 activity.Type: GrantFiled: October 29, 2014Date of Patent: June 21, 2016Assignee: Pharmacyclics LLCInventors: Joseph J. Buggy, Sriram Balasubramanian, Erik Verner, Vincent W. F. Tai, Chang-Sun Lee
-
Patent number: 9371282Abstract: 3-aza-bicyclo[3.1.0]hexane-6-carboxylic acid amide derivatives which are agonists of somatostatin receptor subtype 4 (SSTR4), useful for preventing or treating medical disorders related to SSTR4.Type: GrantFiled: May 12, 2014Date of Patent: June 21, 2016Assignee: Centrexion Therapeutics CorporationInventors: Riccardo Giovannini, Yunhai Cui, Henri Doods, Marco Ferrara, Stefan Just, Raimund Kuelzer, Iain Lingard, Rocco Mazzaferro, Klaus Rudolf
-
Patent number: 9371283Abstract: The present invention is directed to a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula (I) are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula (I) and its therapeutic use.Type: GrantFiled: March 30, 2011Date of Patent: June 21, 2016Assignee: Tetraphase Pharmaceuticals, Inc.Inventors: Xiao-Yi Xiao, Roger Clark, Diana Hunt, Magnus Rönn, Louis Plamondon, Minsheng He, Joyce Sutcliffe, Trudy Grossman
-
Pro-drugs of NSAIAS with very high skin and membranes penetration rates and their new medicinal uses
Patent number: 9371284Abstract: The novel positively charged pro-drugs of NSAIAs in the general formulas (1, 2a, 2b, 2c, or 2d) “Structure 1, 2a, 2b, 2c, or 2d” were designed and synthesized. The compounds of the general formulas (1, 2a, 2b, 2c, or 2d) “Structure 1, 2a, 2b, 2c, or 2d” indicated above can be prepared from metal salts, organic base salts, or immobilized base salts of NSAIAs with suitable halide compounds. The positively charged amino groups in the pro-drugs in this invention largely increase the solubility of the drugs in water and will bond to the negative charge on the phosphate head group of membrane. Thus, the local concentration of the outside of the membrane or skin will be very high and will facilitate the passage of these pro-drugs from a region of high concentration to a region of low concentration. This bonding will disturb the membrane a little bit and may make some room for the lipophilic portion of the pro-drug.Type: GrantFiled: June 4, 2007Date of Patent: June 21, 2016Assignee: Techfields Pharma Co., Ltd.Inventors: Chongxi Yu, Lina Xu -
Patent number: 9371285Abstract: The present disclosure relates to novel compounds, compositions containing same and methods for treating or preventing a condition associated with a deficient insulin secretion such as diabetes and metabolic syndrome in a subject in need thereof.Type: GrantFiled: July 31, 2012Date of Patent: June 21, 2016Assignee: VAL-CHUM, LIMITED PARTNERSHIPInventors: Murthy Madiraju, Marc Prentki, Erik Joly
-
Patent number: 9371286Abstract: The present invention relates to a pharmaceutical composition for inhibiting angiogenesis and a novel sulfonyl amide derivative compound which can be useful for the prevention or treatment of angiogenesis-related diseases or disorders. Since the compound used as an active ingredient in the pharmaceutical composition of the invention is specifically bound to UQCRB and inhibits biological functions thereof, apoptosis is not induced and angiogenic responses are inhibited. Therefore, the compound used as an active ingredient in the pharmaceutical composition of the invention can be useful as an effective and safe angiogenesis inhibitory agent.Type: GrantFiled: May 23, 2011Date of Patent: June 21, 2016Assignee: INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITYInventors: Ho Jeong Kwon, Gyoon Hee Han, Hye Jin Jung, Jeong Jea Seo
-
Patent number: 9371287Abstract: The invention provides a process for the preparation of a compound of Formula 1, comprising coupling a carboxylic acid of Formula 2 with an aniline of Formula 3 in the presence of a coupling agent.Type: GrantFiled: May 23, 2014Date of Patent: June 21, 2016Assignee: Vertex Pharmaceuticals IncorporatedInventors: John DeMattei, Adam R. Looker, Bobbianna Neubert-Langille, Martin Trudeau, Stefanie Roeper, Michael P. Ryan, Dahrika Milfred Yap Guerette, Brian R. Krueger, Peter D. J. Grootenhuis, Fredrick F. Van Goor, Martyn C. Botfield, Gregor Zlokarnik
-
Patent number: 9371288Abstract: The present disclosure relates to crystalline solid forms of [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid, the process of preparing the forms, and pharmaceutical compositions and methods of use thereof.Type: GrantFiled: October 21, 2014Date of Patent: June 21, 2016Assignee: FibroGen, Inc.Inventors: Claudia Witschi, Jung Min Park, Michael D. Thompson, Michael John Martinelli, David A. Yeowell, Michael P. Arend
-
Patent number: 9371289Abstract: The present invention provides a compound of the Formula I: wherein R is H or F; or a pharmaceutically acceptable salt thereof.Type: GrantFiled: May 9, 2014Date of Patent: June 21, 2016Assignee: Eli Lilly and CompanyInventor: Jeremy Schulenburg York
-
Patent number: 9371290Abstract: The invention relates to pyridazinone and pyridone compounds having formula (I) or (I?), and pharmaceutically acceptable salts, hydrates, and solvates thereof (I) wherein R1/R4 and X and X3 are as defined in the claims. The invention further relates to their use as inhibitors of copper-containing amine oxidases. The present invention also relates to the preparation of the aforementioned compounds and to pharmaceutical compositions comprising as an active ingredient(s) one or more of the aforementioned compounds, pharmaceutically acceptable salts, hydrates, or solvates thereof.Type: GrantFiled: March 6, 2012Date of Patent: June 21, 2016Assignee: BIOTIE THERAPIES CORPORATIONInventors: Marjo Pihlavisto, David Smith, Auni Juhakoski, Ferenc Fulop, Laszlo Lazar, Istvan Szatmari, Ferenc Miklos, Zsolt Szakonyi, Lorand Kiss, Marta Palko
-
Patent number: 9371291Abstract: A process for the manufacture of the calcium salt of (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid, useful as an HMGCoA reductase inhibitor, from a compound of the formula (7) wherein A is an acetal or ketal protecting group and R is alkyl, via isolated crystalline compounds of the formula (8) or of formula (10) is described. Crystalline intermediates of formulae 7, 8 and 10 are also described.Type: GrantFiled: July 19, 2011Date of Patent: June 21, 2016Assignees: AstraZeneca UK Limited, Shionogi & Company LimitedInventors: Tetsuo Okada, John Horbury, David Dermot Patrick Laffan
-
Patent number: 9371292Abstract: Disclosed are as represented by Formula (I) a quinazoline derivative and a pharmaceutical acceptable salt thereof, or, an enantiomer, a non-enantiomer, a tautomer, a racemate, a solvate, a metabolic precursor, or a prodrug of both. Also disclosed are a preparation method therefor, an intermediate, a pharmaceutical composition having the quinazoline derivative, and an application thereof. The quinazoline derivative of the present invention is provided with improved anti-tumor activity.Type: GrantFiled: July 27, 2012Date of Patent: June 21, 2016Assignees: SHANGHAI PHARMACEUTICALS HOLDINGS CO., LTD., ZHEJIANG UNIVERSITYInventors: Guangxin Xia, Jingkang Shen, Yongping Yu, Wenteng Chen, Chunchun Zhang, Yu Hao, Jing Zhang, Bojun Li, Xuejun Liu
-
Patent number: 9371293Abstract: The present invention relates to a composition comprising an isoxazoline compound, the isoxazoline compound being dispersed in a solid vehicle of one or more polymer compounds selected from cellulose polymers and vinyl polymers.Type: GrantFiled: October 21, 2014Date of Patent: June 21, 2016Assignee: Sumitomo Chemical Company, LimitedInventors: Naonobu Nishiguchi, Kaori Ikari
-
Patent number: 9371294Abstract: The present invention relates to cycloalkenyl aryl derivatives, isomers thereof, pharmaceutically acceptable salts thereof, hydrates thereof, or solvates thereof; a method for preparing the derivatives; and pharmaceutical compositions containing the same. The compounds of the present invention show the effect of CETP activity inhibition. It means that the compounds can increase HDL-cholesterol and decrease LDL-cholesterol.Type: GrantFiled: April 12, 2012Date of Patent: June 21, 2016Assignee: CHONG KUN DANG PHARMACEUTICAL CORP.Inventors: SeoHee Lee, Jung Taek Oh, JaeKwang Lee, JaeWon Lee, Suyeal Bae, Nina Ha, Sera Lee
-
Patent number: 9371295Abstract: The present invention relates to compounds of formula (I) and (IV), and pharmaceutically acceptable salts, tautomers, stereoisomers thereof, which are inhibitors of histone deacetylase (HDAC). The compounds of the present invention are for use in the treatment of disorders that are ameliorated by inhibition of HDAC such as cancer and hemoglobinopathies like ?-thalassemia or sickle cell anemia.Type: GrantFiled: August 7, 2013Date of Patent: June 21, 2016Assignees: IRBM-SCIENCE PARK S.P.A., C.N.C.C.S. SCARL COLLEZIONE NAZIONALE DEI COMPOSTI CHIMICI E CENTRO SCREENINGInventors: Sergio Altamura, Alberto Bresciani, Giulia Breveglieri, Danilo Fabbrini, Roberto Gambari, Steven Harper, Ralph Laufer, Edith Monteagudo, Emanuela Nizi, Paola Pace, Vincenzo Summa
-
Patent number: 9371296Abstract: The present invention relates to bicyclic 1,3,4-oxadiazole derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.Type: GrantFiled: November 10, 2015Date of Patent: June 21, 2016Assignee: Allergan, Inc.Inventors: Ling Li, Janet A. Takeuchi, Ken Chow, Wha Bin Im, Michael E. Garst
-
Patent number: 9371297Abstract: The present invention provides novel conformationally-defined macrocyclic compounds that can function as selective modulators of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as agonists of the ghrelin receptor and as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, central nervous system disorders, bone disorders, genetic disorders, hyperproliferative disorders and inflammatory disorders.Type: GrantFiled: February 8, 2008Date of Patent: June 21, 2016Assignee: Ocera Therapeutics, Inc.Inventors: Hamid Hoveyda, Graeme L. Fraser, Kamel Benakli, Sophie Beauchemin, Martin Brassard, Eric Marsault, Luc Oullet, Mark L. Peterson, Zhigang Wang
-
Patent number: 9371298Abstract: Processes and intermediates for the preparation of compounds of the Formula I and the pharmaceutically acceptable salts, prodrugs, solvates and hydrates thereof, wherein R1, R2, and R3 have the definitions provided herein.Type: GrantFiled: November 10, 2014Date of Patent: June 21, 2016Assignees: Pfizer Inc., OSI Pharmaceuticals, LLCInventors: David B. Damon, Brian P. Jones
-
Patent number: 9371299Abstract: The present invention relates to new thiadiazolidinediones of formula (I), or any pharmaceutically acceptable salt, solvate or prodrug thereof, and its use in the treatment of a disease in which glycogen synthase kinase 3 (GSK-3) is involved, particularly neurodegenerative diseases, inflammatory and autoimmune diseases and cardiovascular disorders. Additionally, there is provided a process for preparing such compounds, as well as pharmaceutical compositions comprising them.Type: GrantFiled: February 22, 2013Date of Patent: June 21, 2016Assignee: ASD THERAPEUTICS PARTNERS, LLCInventors: Miguel Medina Padilla, Juan Manuel Domínguez Correa, Javier De Cristobal Blanco, Ana Fuertes Huerta, Jorge Sánchez-Quesada, Javier López Ogalla, Susana Herrero Santos, María Ángeles Pérez de la Cruz Moreno, Olga Martínez Montero, Beatriz Rodríguez Salguero, Francisco Palomo Nicolau
-
Patent number: 9371300Abstract: Methods and compositions are provided for the manufacture of an epoxide. In one embodiment, the invention provides a process for the manufacture of an epoxide including providing an olefin, an oxidant, alkaline earth metal ions, a catalyst component, a buffer component, and water to form a reaction mixture and reacting the olefin with the oxidant in the reaction mixture.Type: GrantFiled: October 7, 2013Date of Patent: June 21, 2016Assignee: Evonik Degussa GmbHInventors: Mark Kapellen, Joachim Lienke, Jimmy Antonius Van Rijn
-
Patent number: 9371301Abstract: A compound represented by the general formula (C): (wherein R101 represents a substituted or unsubstituted aromatic heterocyclic group, R102, R103, R104 and R105 may be the same or different, and each represents a hydrogen atom, a halogen atom, an alkyl group having 1 to 3 carbon atoms, or a haloalkyl group having 1 to 3 carbon atoms, and R106 represents a hydrogen atom, or a saturated or unsaturated hydrocarbon group which is a straight or branched chain having 1 to 12 carbon atoms, but excluded is the case where R101 is a 3-furyl group, R102, R103, R104 and R105 are all methyl groups, and R106 is a methyl group, a 4-methyl-3-pentenyl group or a 4,8-dimethyl-3,7-nonadienyl group); or a pharmaceutically acceptable salt thereof has selective inhibitory activity on hypoxic cell growth in a broad range of the concentration and therefore is useful as an active ingredient of a medicament for cancer prevention or treatment.Type: GrantFiled: May 6, 2011Date of Patent: June 21, 2016Assignee: Osaka UniversityInventors: Motomasa Kobayashi, Naoyuki Kotoku, Masayoshi Arai, Takashi Kawachi
-
Patent number: 9371302Abstract: Compounds, methods, and compositions are provided for the treatment of cancer, neurological disorders, and fibrotic disorders. Specifically, the invention includes administering an effective amount of a compound of Formula I, II, or III, or a pharmaceutically acceptable composition, salt, isotopic analog, prodrug, or combination thereof, to a subject suffering from a cancer, neurological disorder, or fibrotic disorder.Type: GrantFiled: March 28, 2014Date of Patent: June 21, 2016Assignee: AvoScience, LLCInventor: Richard Huber
-
Patent number: 9371303Abstract: A compound with a diphenylmethane moiety having an inhibitory activity against sodium-dependent glucose cotransporter 2 (SGLT2) being present in the intestine and kidney is disclosed. A pharmaceutical composition including the compound as an active ingredient, which is useful for preventing or treating metabolic disorders, particularly diabetes is disclosed. A method for preparing the compound, and a method for preventing or treating metabolic disorders, particularly diabetes, by using the compound is provided.Type: GrantFiled: January 9, 2015Date of Patent: June 21, 2016Assignee: GREEN CROSS CORPORATIONInventors: Soongyu Choi, Kwang-Seop Song, Suk Ho Lee, Min Ju Kim, Hee Jeong Seo, Eun-Jung Park, Younggyu Kong, So Ok Park, Hyunku Kang, Myung Eun Jung, Kinam Lee, Hyun Jung Kim, Jun Sung Lee, Min Woo Lee, Mi-Soon Kim, Dong Ho Hong, Misuk Kang